Bicycle Therapeutics (NASDAQ:BCYC) given new $14.00 price target at Needham & Company LLC. July 30, 2026 Key points. * Needham lowered its price target for Bicycle Therapeutics from $15 to $14 while maintaining a "buy" rating, implying substantial upside from the stock's prior close. The broader analyst consensus is "Hold," with an average target of $13.86. * Bicycle Therapeutics shares traded at about $4.00, near their 12-month low of $3.81, after the company reported a quarterly loss of $0.72 per share - worse than the $0.37 consensus estimate - and revenue of just $0.63 million. * Institutional ownership remains high at 86.15%, with GSK and Schroder Investment Management among recent new investors; meanwhile, CEO Kevin Lee sold shares primarily to cover tax obligations tied to vested equity awards. * MarketBeat previews top five stocks to own in August. Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) had its price objective cut by research analysts at Needham & Company LLC from $15.00 to $14.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Needham & Company LLC's target price suggests a potential upside of 249.56% from the stock's previous close. Several other equities research analysts have also recently weighed in on the company. Weiss Ratings restated a "sell (e+)" rating on shares of Bicycle Therapeutics in a research note on Wednesday, July 8th. Morgan Stanley cut their price objective on shares of Bicycle Therapeutics from $13.00 to $12.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 8th. Wall Street Zen upgraded shares of Bicycle Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday, June 27th. Jefferies Financial Group restated a "buy" rating and issued a $12.00 target price on shares of Bicycle Therapeutics in a report on Thursday, April 30th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Bicycle Therapeutics in a research report on Wednesday, June 3rd. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $13.86. Bicycle Therapeutics price performance. Shares of Bicycle Therapeutics stock traded up $0.14 during trading on Thursday, hitting $4.00. 344,104 shares of the stock were exchanged, compared to its average volume of 428,018. The firm's 50-day moving average price is $4.21 and its 200 day moving average price is $4.95. The stock has a market cap of $279.59 million, a price-to-earnings ratio of -1.27 and a beta of 1.55. Bicycle Therapeutics has a 12-month low of $3.81 and a 12-month high of $9.16. Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.35). The business had revenue of $0.63 million during the quarter. Bicycle Therapeutics had a negative net margin of 344.95% and a negative return on equity of 35.74%. As a group, research analysts forecast that Bicycle Therapeutics will post -1.97 earnings per share for the current year. Insider transactions at Bicycle Therapeutics. In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,905 shares of the company's stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $4.27, for a total transaction of $25,214.35. Following the completion of the sale, the chief executive officer directly owned 605,408 shares of the company's stock, valued at $2,585,092.16. This represents a 0.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 9,977 shares of company stock valued at $42,702. Insiders own 22.00% of the company's stock. Institutional inflows and outflows. Institutional investors have recently modified their holdings of the stock. GSK plc acquired a new stake in shares of Bicycle Therapeutics during the fourth quarter worth $10,829,000. Schroder Investment Management Group acquired a new position in Bicycle Therapeutics in the 4th quarter valued at $3,976,000. Renaissance Technologies LLC raised its position in Bicycle Therapeutics by 72.8% during the 1st quarter. Renaissance Technologies LLC now owns 979,300 shares of the company's stock worth $4,544,000 after buying an additional 412,700 shares during the last quarter. Woodline Partners LP purchased a new position in Bicycle Therapeutics during the 1st quarter worth $3,088,000. Finally, Birchview Capital LP lifted its stake in shares of Bicycle Therapeutics by 200.5% in the 4th quarter. Birchview Capital LP now owns 462,700 shares of the company's stock worth $3,276,000 after acquiring an additional 308,700 shares during the period. Institutional investors and hedge funds own 86.15% of the company's stock. Bicycle Therapeutics company profile. Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company's core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology. Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Bicycle Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list. While Bicycle Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The space race is growing fast, and you don't have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Bicycle Therapeutics extends cash runway into 2030. 29 Jul, 2026 Tony Quested Bicycle Therapeutics, a transatlantic Pharma company headquartered at Granta Park in Cambridge, has broadened its cash runway into 2030 through a mix of cost savings on non-core research and no-nonsense headcount reductions. Bicycle CEO, Kevin Lee. Credit - Bicycle Therapeutics. At the same time it reports major strides in taking its cancer solutions ever closer to market. The company points to encouraging data presented at industry summits AACR and ASCO that it says provided further validation of the potential of Bicycle(R) technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities Cash and equivalents of $510.1 million have been reported for Q2 as at June 30. The results scarcely moved the needle on its Nasdaq stock when the markets opened this afternoon (Thursday) with the share price still only marginally ahead of the 52-week low. Bicycle is pioneering a new and differentiated class of therapeutics and CEO Kevin Lee was pleased with the progress made during the second quarter of the financial year. He said: "Its financial discipline with refined focus on nuzefatide pevedotin and its next-generation Bicycle conjugate pipeline, including Bicycle(R) Radioconjugates (BRC(R), leaves Business Weekly well capitalised to pursue its mission to help patients to not only live longer, but also live well. "The encouraging data Business Weekly presented during the quarter continue to deepen its belief in the potential of its technology to deliver oncology therapeutics with a superior benefit/risk profile against high-value targets like EphA2 and Nectin-4, the former being historically considered undruggable using antibody-based approaches. "We believe this profile provides a strong rationale for developing nuzefatide in recurrent pancreatic cancer, where we successfully dosed our first patient in the ongoing Phase 2 trial in April. We remain on track to begin the Phase 1 trial for BT1702, our MT1-MMP targeting BRC, in 2027, backed by compelling human imaging data validating the targeting precision and translatability of our Bicycle(R) technology." Dr Lee also welcomed world-renowned oncologist Professor Thomas Powles to Bicycle's Clinical Advisory Board and said his deep clinical insights and distinguished leadership in urothelial cancers would be instrumental as Bicycle accelerated its efforts to deliver precision-targeted therapies for patients. Dr. Powles is a Professor of Genitourinary Oncology and Director of Barts Cancer Centre at St Bartholomew's Hospital, and lead for solid tumour Research at Barts Cancer Institute, London. He is an international leader in the treatment of urothelial cancers, with a research focus spanning from Phase 1 to randomised Phase 3 clinical trials, particularly in translational Phase 2 studies investigating novel targeted and immune therapies. He has played a critical role in leading over 20 randomised clinical trials, resulting in multiple U.S. Food and Drug Administration (FDA) and European Medicines Agency approvals. Despite the mainly negative market reaction to Bicycle's consistent advances, data presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 highlighted significant opportunities for nuzefatide pevedotin (nuzefatide), a potentially first-in-class EphA2 targeting Bicycle(R) Drug Conjugate (BDC(R), in EphA2 expressing cancers. Results from the Phase 1/2 trial evaluating nuzefatide 6.5mg/m2 once every two weeks (Q2W) plus nivolumab 480mg once every four weeks (Q4W) in 14 patients with metastatic urothelial cancer who had previously progressed on a checkpoint inhibitor while on enfortumab vedotin) showed a differentiated safety profile as well as promising anti-tumour activity. Bicycle believes that all the data from the trial underscored the therapeutic potential for nuzefatide in EphA2-expressing cancers, including pancreatic cancer. The company is actively enrolling patients in a Phase 2 clinical trial to evaluate efficacy, safety, and pharmacokinetics of nuzefatide in adult patients with recurrent PDAC. The first patient was successfully dosed in April. Additional human imaging data of a Bicycle(R) Imaging Agent (BIA) targeting EphA2 in patients with PDAC were presented at AACR Annual Meeting 2026. The German Cancer Consortium (DKTK), part of a cooperative network with the German Cancer Research Center, presented human imaging data conducted with a Bicycle(R) molecule targeting EphA2 labelled with gallium-68 (EphA2 BIA) in seven patients with histologically confirmed PDAC. Bicycle believes these data validate the potential of EphA2 as a novel target in the treatment of cancer, demonstrate the translatability of preclinical data and highlight the potential of Bicycle(R) molecules for targeted radioligand therapies and radiopharmaceutical imaging. The company continues to advance its emerging radioligand pipeline, with the initiation of the first company-sponsored radioligand clinical trial for BT1702, an MT1-MMP targeting BRC, expected in 2027. Initial Duravelo-2 data presented at 2026 American Society of Clinical Oncology Annual Meeting demonstrates encouraging response rates comparable to published data for standard of care (SOC) and a potentially differentiated safety profile in previously untreated patients with mUC. peripheral neuropathy, It is also on record in the US that not one broker is recommending shareholders to sell Bicycle stock. The vast majorly, in fact, are recommending a 'buy.' The cash and equivalents of $510.1m compared to $628.1m in December 31, 2025. R & D costs were also slashed to $41.2m for the three months ended June 30 compared to $71m for the previous quarter. This was chiefly due to lower clinical program expenses for zelenectide, decreased personnel-related costs and share-based compensation due to redundancies announced in March, as well as decreased discovery, platform and other expenses, offset by lower U.K. R & D tax credits. General and administrative expenses were down to $14m from $18.5m due to lower professional and consulting fees and decreased personnel-related costs and share-based compensation due to the job cuts. Net loss was slashed from $79m to $50.3m year-on-year. While Bicycle is headquartered in Cambridge, UK, many key functions and members of its leadership team are based in Lexington, Mass. Tony Quested [email protected]